Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
NLNK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.36%80.240.9%$594.15m
CELGCelgene Corporation
1.57%138.861.1%$558.43m
AMGNAmgen Inc.
2.36%186.191.1%$449.83m
BIIBBiogen Inc.
2.62%344.471.2%$386.48m
REGNRegeneron Pharmaceuticals, Inc.
-0.70%442.562.7%$317.95m
ALNYAlnylam Pharmaceuticals, Inc
-2.61%118.7010.7%$256.31m
VRTXVertex Pharmaceuticals Incorporated
0.23%155.051.9%$221.45m
INCYIncyte Corporation
-0.82%115.642.5%$207.97m
ALXNAlexion Pharmaceuticals, Inc.
1.65%143.161.9%$182.04m
ILMNIllumina, Inc.
0.12%206.483.5%$139.87m
EXELExelixis, Inc.
-2.48%28.306.5%$135.44m
CLVSClovis Oncology, Inc.
-3.85%81.3216.5%$124.68m
BLUEBluebird Bio, Inc.
-2.16%140.2017.3%$118.12m
SRPTSarepta Therapeutics, Inc.
1.95%51.7216.9%$110.02m
BMRNBioMarin Pharmaceutical Inc.
-1.18%93.544.4%$103.49m

Company Profile

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.